Ozempic. Wegovy. Mounjaro. GLP-1 medications occupy unprecedented territory today – sold everywhere from Costco to aesthetic clinics.

Our healthcare expert and Head of Strategy, Deborah Stafford-Watson, explains why the old pharma playbook no longer applies and why the brands that move first will shape the future of the category.

Read the PharmaTimes Magazine here to find out what it really takes to win the GLP-1 race in 2026.

Deborah Stafford-Watson


Deborah Stafford-Watson, Head of Strategy

Deborah has worked with brands – from start ups to blue chips – for over 20 years to help them define their purpose in the world, develop breakthrough ideas and design experiences that drive commercial results.

An experienced brand strategist and creative thinker, Deborah leads Elmwood’s London strategy team to elevate our strategic offer and partner with clients to drive meaningful change from intent to impact. A proud winner of multiple DBA gold awards, Deborah has shaped strategies for the BBC, Haleon, LW Theatres, Heck, the FA, SSE,  Perrigo and Pizza Express across corporate, consumer and healthcare.